A fusion protein made of an antigen peptide presented with MHC class I and XCL1 plus an immune adjuvant contributed to reducing tumor growth in a mouse melanoma model in combination with an anti-PD-1 blockade [52]. This evidence concerns the gene XCL1 and melanoma.